← Back to Search

Metabolic Testing for Type 1 Diabetes (LTD Trial)

Q: Are researchers actively seeking out participants for this research?

According to information hosted on clinicaltrials.gov, this trial is in need of participants and was first published on May 9th 2022 before being updated on October 31st the same year.

Q: Does this trial offer enrollment to individuals under 45 years of age?

This trial is seeking participants aged 18-45.

Q: How many volunteers are engaged in this clinical experiment?

Affirmative. The clinical trial details posted on clinicaltrials.gov verify that this medical study is actively seeking participants, having been initially listed on May 9th 2022 and updated most recently in October 2021. 30 patients will be enrolled from 1 location for the purpose of this research initiative.

Q: Who is eligible to join this clinical investigation?

This research demands thirty individuals, aged between 18 and 45 years old that have been diagnosed with <a href="https://www.withpower.com/clinical-trials/type-1-diabetes">type 1 diabetes</a> mellitus. It is imperative for potential participants to also fulfill the following prerequisites: post-prandial glucose &#x3C;140 mg/dL; a body mass index ranging from 18.5-30 kg/m2; fasting plasma triglyceride concentration of less than 150 mg/dL; overnight fasted blood glucose level below 100mg/dL; HbA1c lower than 5.6%; stable insulin regimen (MIDI or CSII) for at least two months before screening commencement; no use of diabetic drugs apart

N/A

Recruiting

Led By Bettina Mittendorfer

Research Sponsored by University of Missouri-Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Non-obese (body mass index ≥18.5<30.0 kg/m2)

No use of diabetes medications other than insulin

Timeline

Screening 3 weeks

Treatment Varies

Follow Up one time, at baseline (this is a cross-sectional, observational study, no intervention)

Awards & highlights

LTD Trial Summary

This trial will compare how type 1 diabetes affects apolipoprotein and triglyceride levels, which are risk factors for heart attack and stroke.

Who is the study for?

This study is for adults aged 18-45 with Type 1 Diabetes who haven't had severe hypoglycemia recently, are on a stable insulin regimen without other diabetes meds, aren't obese, and have certain levels of blood fats and sugars. Healthy controls must meet similar criteria but also have normal HbA1c levels.Check my eligibility

What is being tested?

The trial aims to understand how Type 1 Diabetes affects the risk of heart disease by comparing fat and protein particles in the blood (apolipoproteins and triglycerides) between those with T1D and healthy individuals through metabolic testing.See study design

What are the potential side effects?

Since this trial involves metabolic testing rather than drug treatment, side effects may be minimal but could include discomfort or bruising from blood draws or potential reactions to any substances used during testing.

LTD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My BMI is between 18.5 and 30.

Select...

I only use insulin for my diabetes.

Select...

I am not pregnant, breastfeeding, and still have my menstrual periods.

Select...

I am between 18 and 45 years old.

LTD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ one time, at baseline (this is a cross-sectional, observational study, no intervention)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~one time, at baseline (this is a cross-sectional, observational study, no intervention)

This trial's timeline: 3 weeks for screening, Varies for treatment, and one time, at baseline (this is a cross-sectional, observational study, no intervention) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Apolipoprotein C turnover rate

Secondary outcome measures

Apolipoprotein B-100 concentration

Apolipoprotein B-100 turnover rate

Apolipoprotein C concentration

+2 more

LTD Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Control groupExperimental Treatment1 Intervention

Healthy control group

Group II: T1D groupActive Control1 Intervention

T1D group

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Missouri-ColumbiaLead Sponsor

362 Previous Clinical Trials

628,084 Total Patients Enrolled

Washington University School of MedicineLead Sponsor

1,936 Previous Clinical Trials

2,299,660 Total Patients Enrolled

University of WashingtonOTHER

1,741 Previous Clinical Trials

1,847,736 Total Patients Enrolled

Media Library

Control group Clinical Trial Eligibility Overview. Trial Name: NCT05179954 — N/A

Type 1 Diabetes Research Study Groups: Control group, T1D group

Type 1 Diabetes Clinical Trial 2023: Control group Highlights & Side Effects. Trial Name: NCT05179954 — N/A

Control group 2023 Treatment Timeline for Medical Study. Trial Name: NCT05179954 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers actively seeking out participants for this research?

"According to information hosted on clinicaltrials.gov, this trial is in need of participants and was first published on May 9th 2022 before being updated on October 31st the same year."

Answered by AI

Does this trial offer enrollment to individuals under 45 years of age?

"This trial is seeking participants aged 18-45."

Answered by AI

How many volunteers are engaged in this clinical experiment?

"Affirmative. The clinical trial details posted on clinicaltrials.gov verify that this medical study is actively seeking participants, having been initially listed on May 9th 2022 and updated most recently in October 2021. 30 patients will be enrolled from 1 location for the purpose of this research initiative."

Answered by AI

Who is eligible to join this clinical investigation?

"This research demands thirty individuals, aged between 18 and 45 years old that have been diagnosed with type 1 diabetes mellitus. It is imperative for potential participants to also fulfill the following prerequisites: post-prandial glucose <140 mg/dL; a body mass index ranging from 18.5-30 kg/m2; fasting plasma triglyceride concentration of less than 150 mg/dL; overnight fasted blood glucose level below 100mg/dL; HbA1c lower than 5.6%; stable insulin regimen (MIDI or CSII) for at least two months before screening commencement; no use of diabetic drugs apart"

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Lipoprotein Kinetics in T1D

Bettina Mittendorfer 2022. "Lipoprotein Kinetics in T1D". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05179954.